Lv11
70 积分 2025-07-08 加入
Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors
1小时前
待确认
Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection
25天前
已完结
Expanding Access to Cancer Immunotherapy: A Systematic Review of Low-Dose PD-(L)1 Inhibitor Strategies
30天前
已完结
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
1个月前
已完结
Capecitabine: have we got the dose right?
1个月前
已完结
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
1个月前
已完结
Resistance is futile with fourth-generation EGFR inhibitors
1个月前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
1个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1个月前
已完结
Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology
2个月前
已完结
皖公网安备34019202002308
